On Thursday, Abbott Laboratories said it would buy Minnesota based, medical technology company St. Jude Medical Inc for $25 billion. Te main aim is to enlarge its heart device business. However, investors are worried that this acquisition will most probably not pay off like it's promised. It will be a cash-and-stock acquisition. Abbott plans to borrow money for the deal.
No matter how Valeant Pharmaceuticals International Inc. tries to win investors favor but its situation gets worse. The company reeling with troubles for months offered a financial outlook on Tuesday which turned out to be worse than people feared. Stocks dropped and the company's market value was cut into almost half.
Tax Fairness Advocates say Pfizer might Avoid Paying $35 Billion in Tax through Merger Deal with AllerganSubmitted by Justin Sorkin on Fri, 02/26/2016 - 08:50
In a Money Saving Effort Johnson & Johnson will Trim Six Percent Jobs in its Medical-Device DivisionSubmitted by Ryan Bilanich on Wed, 01/20/2016 - 07:45
In a recent step taken by Johnson & Johnson to perk up its struggling business, the company said on Tuesday, it would trim approximately three thousand jobs in the medical devices division.
The positions that will be eliminated accounts for 2.5 percent of the 127,000 global employees and six percent of its medical-device division.
Martin Shkreli's arrest has brought troubles for the pharma companied that he was connected to. KaloBios, the San Francisco based drug company has recently filed for bankruptcy. It earlier fired Shkreli as its CEO.
Things that Martin Shkreli files touches seems to with away and that's seems so true looking at the companies that he was linked to.